|
1
|
Liaw YF, Kao JH, Piratvisuth T, Chan HL,
Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, et al:
Asian-Pacific consensus statement on the management of chronic
hepatitis B: A 2012 update. Hepatol Int. 6:531–561. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marcellin P, Zoulim F, Hezode C, Causse X,
Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, et
al: Effectiveness and safety of tenofovir disoproxil fumarate in
chronic hepatitis B: A 3-year, prospective, real-world study in
france. Dig Dis Sci. 61:3072–3083. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK,
Chen SM, Hu JJ, Lin HH, Zhao LL, Mu SC, et al: Efficacy of maternal
tenofovir disoproxil fumarate in interrupting mother-to-infant
transmission of hepatitis B virus. Hepatology. 62:375–386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kitrinos KM, Corsa A, Liu Y, Flaherty J,
Snow-Lampart A, Marcellin P, Borroto-Esoda K and Miller MD: No
detectable resistance to tenofovir disoproxil fumarate after 6
years of therapy in patients with chronic hepatitis B. Hepatology.
59:434–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Batirel A, Guclu E, Arslan F, Kocak F,
Karabay O, Ozer S, Turanli M and Mert A: Comparable efficacy of
tenofovir versus entecavir and predictors of response in
treatment-naive patients with chronic hepatitis B: A multicenter
real-life study. Int J Infect Dis. 28:153–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petersen J, Heyne R, Mauss S, Schlaak J,
Schiffelholz W, Eisenbach C, Hartmann H, Wiese M, Boeker K, Loehr
HF, et al: Effectiveness and safety of tenofovir disoproxil
fumarate in chronic hepatitis B: A 3-year prospective field
practice study in germany. Dig Dis Sci. 61:3061–3071. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kozielewicz D, Halota W and
Wietlicka-Piszcz M: Tenofovir rescue therapy in chronic hepatitis B
patients who failed previous nucleoside analogue treatment. Hepatol
Int. 10:302–309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia H, Ding F, Chen J, Zhang Y, Xiang D,
Lian J, Zeng L, Yu L, Hu J, Li Y, et al: LAM add-on ADV combination
therapy or ETV monotherapy for CHB patients with suboptimal
response to ADV. Ann Hepatol. 14:175–180. 2015.PubMed/NCBI
|
|
9
|
Wang M, Da Y, Cai H, Lu Y, Wu L and Jia J:
Telbivudine myopathy in a patient with chronic hepatitis B. Int J
Clin Pharm. 34:422–425. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hannon H, Bagnis CI, Benhamou Y, Beaufils
H, Sullivan M, Brosgart C, Izzedine H, Poynard T and Deray G: The
renal tolerance of low-dose adefovir dipivoxil by
lamivudine-resistant individuals co-infected with hepatitis B and
HIV. Nephrol Dial Transplant. 19:386–390. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang J, Wei F, Wang LH, Hai-Bo YU, Zhi LU,
Wang Z, et al: Effects of different serum calcium levels on
vascular calcification and cardiovascular death in patients with
end-stage renal disease. J Tianjin Med University. 2017.(In
Chinese).
|
|
12
|
Sharma A, Thompson JA, Repaka A and
Mehnert JM: Ipilimumab administration in patients with advanced
melanoma and hepatitis B and C. J Clin Oncol. 31:e370–e372. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song WJ and Lu YP: Characteristics of
liver histology and the correlated index in patients with chronic
hepatitis B and normal ALT levels. Chin Foreign Med Res. 2013.(In
Chinese).
|
|
14
|
Thapa BR and Walia A: Liver function tests
and their interpretation. Indian J Pediatr. 74:663–671. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JH, Jung SW, Byun SS, Shin JW, Park
BR, Kim MH, Kim CJ and Park NH: Efficacy and safety of tenofovir in
nucleos(t)ide-naive patients with genotype C chronic hepatitis B in
real-life practice. Int J Clin Pharm. 37:1228–1234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayaz C, Celen MK, Dal T, Deveci O, Bayan
K, Mert D, Oruç E, Özcan N, Kandemir I and Dal MS: Tenofovir
disoproxil fumarate treatment in HbeAg-positive patients. Infez
Med. 23:31–35. 2015.PubMed/NCBI
|
|
17
|
Idilman R, Gunsar F, Koruk M, Keskin O,
Meral CE, Gulsen M, Elhan AH, Akarca US and Yurdaydin C: Long-term
entecavir or tenofovir disoproxil fumarate therapy in
treatment-naive chronic hepatitis B patients in the real-world
setting. J Viral Hepat. 22:504–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim BG, Jung SW, Kim EH, Kim JH, Park JH,
Sung SJ, Park BR, Kim MH, Kim CJ, Lee BU, et al: Tenofovir-based
rescue therapy for chronic hepatitis B patients who had failed
treatment with lamivudine, adefovir, and entecavir. J Gastroenterol
Hepatol. 30:1514–1521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lo AO, Wong VW, Wong GL, Tse YK, Chan HY
and Chan HL: Efficacy of tenofovir switch therapy for
nucleos(t)ide-experienced patients with chronic hepatitis B.
Aliment Pharmacol Ther. 41:1190–1199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee S, Park JY, Kim DY, Kim BK, Kim SU,
Song K, Ku HJ, Han KH and Ahn SH: Prediction of virologic response
to tenofovir mono-rescue therapy for multidrug resistant chronic
hepatitis B. J Med Virol. 88:1027–1034. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baran B, Soyer OM, Ormeci AC, Gokturk S,
Evirgen S, Akyuz F, Karaca C, Demir K, Besisik F, Onel D, et al:
Tenofovir disoproxil fumarate has a substantial efficacy against
multidrug-resistant strains of hepatitis B virus. Liver Int.
35:2265–2274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Svarovskaia ES, Curtis M, Zhu Y,
Borroto-Esoda K, Miller MD, Berg T, Lavocat F, Zoulim F and
Kitrinos KM: Hepatitis B virus wild-type and rtN236T populations
show similar early HBV DNA decline in adefovir refractory patients
on a tenofovir-based regimen. J Viral Hepat. 20:131–140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van B, ömmel F, de Man RA, Wedemeyer H,
Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K,
Trojan J, et al: Long-term efficacy of tenofovir monotherapy for
hepatitis B virus-monoinfected patients after failure of
nucleoside/nucleotide analogues. Hepatology. 51:73–80. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van B, ömmel F, Trojan J, Deterding K,
Wedemeyer H, Wasmuth HE, Huppe D, Möller B, Bock FJ, Feucht HH and
Berg T: Evolution of adefovir-resistant HBV polymerase gene
variants after switching to tenofovir disoproxil fumarate
monotherapy. Antivir Ther. 17:1049–1058. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park HS, Lee DH, Heo J, Kim GH, Kang DH,
Song GA and Cho M: Correlation of HBV DNA level and viral
breakthrough during lamivudine therapy for chronic hepatitis B.
Korean J Hepatol. 12:173–183. 2006.(In Korean). PubMed/NCBI
|
|
26
|
Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ,
An J, Lee HC and Lee YS: Switching tenofovir disoproxil fumarate
(TDF) plus entecavir combination therapy to TDF monotherapy is safe
and efficacious in patients with multiple drug-resistant chronic
hepatitis B: Randomized trial. J Hepatol. 64:S606–S. 2016.
View Article : Google Scholar
|
|
27
|
Lu L, Yip B, Trinh H, Pan CQ, Han SH, Wong
CC, Li J, Chan S, Krishnan G, Wong CC and Nguyen MH:
Tenofovir-based alternate therapies for chronic hepatitis B
patients with partial virological response to entecavir. J Viral
Hepat. 22:675–681. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park JH, Jung SW, Park NH, Park BR, Kim
MH, Kim CJ, Lee BU, Jeong ID, Kim BG, Bang SJ and Shin JW: Efficacy
of tenofovir-based rescue therapy in lamivudine-resistant chronic
hepatitis B patients with failure of lamivudine and adefovir
combination. Clin Ther. 37:1433–1442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang HL, Lu X, Yang X and Ning Q: Efficacy
of tenofovir-based rescue therapy in patients with
lamivudine-resistant hepatitis B virus: A systematic review and
meta-analysis. Clin Res Hepatol Gastroenterol. 40:447–456. 2016.
View Article : Google Scholar : PubMed/NCBI
|
